Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC

Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC ( Prof Stephen Chan - The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Independent clones in CLL show oligoclonality and early evolution patterns

Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona...

Independent clones in CLL show oligoclonality and early evolution patterns ( Dr Ferran Nadeu - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain )

Breast cancer survivorship

Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg

Breast cancer survivorship ( Dr Luzia Travado, Dr Christina Signorelli and Dr Beverley Lim Høeg )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2...

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Ordronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory...

Dr Anthony Stein - City of Hope, Duarte, USA

$Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )$

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with...

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared...

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy...

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

$POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )$

(Bio) Markers and milestones at the crossroads of mHSPC care 

Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard

(Bio) Markers and milestones at the crossroads of mHSPC care  ( Dr Miguel Ramírez-Backhaus, Prof Jozefina Casuscelli, Prof Gerhardt Attard )

More from ecancer